{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:20:34Z","timestamp":1792783234887,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the effect of osilodrostat and hypercortisolism control on blood pressure (BP) and glycemic control in patients with Cushing\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Pooled analysis of two Phase III osilodrostat studies (LINC 3 and LINC 4), both comprising a 48-week core phase and an optional open-label extension. Changes from baseline in systolic and diastolic BP (SBP and DBP), fasting plasma glucose (FPG), and glycated hemoglobin (HbA\n                      <jats:sub>1c<\/jats:sub>\n                      ) were evaluated during osilodrostat treatment in patients with\/without hypertension or diabetes at baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 210 patients, 82.9% met criteria for hypertension and 40.0% for diabetes at baseline. In patients with hypertension, reductions in mean SBP\/DBP were observed from week (W)12 to W72, and 49.1%\/58.5% of patients with high SBP\/DBP (&gt;\u2009130\/&gt;90 mmHg) at baseline had normotensive levels at W72. Antihypertensive medication dose was reduced\/stopped in 26.8% of patients, and the proportion taking antihypertensive medication decreased from 54.3% at baseline to 47.3% at W72. In patients with diabetes, mean FPG and HbA\n                      <jats:sub>1c<\/jats:sub>\n                      decreased from W12 to W72, and 33.3%\/61.5% with high FPG\/HbA\n                      <jats:sub>1c<\/jats:sub>\n                      (\u2265\u2009100\u00a0mg\/dL\/\u22656.5%) at baseline had normal levels at W72. Antihyperglycemic medication dose was reduced\/stopped in 35.7% of patients, and the proportion taking antihyperglycemic medication decreased from 21.9% at baseline to 17.1% at W72; improvements in SBP\/DBP and FPG\/HbA\n                      <jats:sub>1c<\/jats:sub>\n                      were correlated with improvement in mean urinary free cortisol but not weight change. BP\/glycemic parameters generally remained normal in patients without hypertension\/diabetes at baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with Cushing\u2019s disease and comorbid hypertension\/diabetes receiving osilodrostat had rapid and sustained improvements in SBP\/DBP and glycemic control, respectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-024-01471-3","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T13:33:03Z","timestamp":1737811983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Osilodrostat improves blood pressure and glycemic control in patients with Cushing\u2019s disease: a pooled analysis of LINC 3 and LINC 4 studies"],"prefix":"10.1007","volume":"28","author":[{"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Newell-Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica R.","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly M. K.","family":"Biller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Auchus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Witek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Pedroncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"issue":"9996","key":"1471_CR1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing\u2019s syndrome. Lancet 386(9996):913\u2013927","journal-title":"Lancet"},{"issue":"2","key":"1471_CR2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jama.2023.11305","volume":"330","author":"M Reincke","year":"2023","unstructured":"Reincke M, Fleseriu M (2023) Cushing syndrome: a review. JAMA 330(2):170\u2013181","journal-title":"JAMA"},{"issue":"10418","key":"1471_CR3","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0140-6736(23)01961-X","volume":"402","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Gatto F, Wildemberg LE, Fleseriu M (2023) Cushing\u2019s syndrome. Lancet 402(10418):2237\u20132252","journal-title":"Lancet"},{"issue":"8","key":"1471_CR4","doi-asserted-by":"crossref","first-page":"e13113","DOI":"10.1111\/jne.13113","volume":"34","author":"LT Braun","year":"2022","unstructured":"Braun LT, Vogel F, Reincke M (2022) Long-term morbidity and mortality in patients with Cushing\u2019s syndrome. J Neuroendocrinol 34(8):e13113","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"1471_CR5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-11-1095","volume":"167","author":"RA Feelders","year":"2012","unstructured":"Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing\u2019s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167(3):311\u2013326","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1471_CR6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A (2016) Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol 4(7):611\u2013629","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1471_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11102-023-01343-2","volume":"26","author":"A Mondin","year":"2023","unstructured":"Mondin A, Ceccato F, Voltan G, Mazzeo P, Manara R, Denaro L et al (2023) Complications and mortality of Cushing\u2019s disease: report on data collected over a 20-year period at a referral centre. Pituitary 26(5):551\u2013560","journal-title":"Pituitary"},{"issue":"10","key":"1471_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41574-023-00868-7","volume":"19","author":"M Fleseriu","year":"2023","unstructured":"Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, Langlois F, Melmed S (2023) An individualized approach to the management of Cushing disease. Nat Rev Endocrinol 19(10):581\u2013599","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"1471_CR9","doi-asserted-by":"crossref","first-page":"e240028","DOI":"10.1530\/ERC-24-0028","volume":"31","author":"PB Loughrey","year":"2024","unstructured":"Loughrey PB, Herron B, Cooke S, Weir P, Smyth JE, Mullan KR et al (2024) Insights on epidemiology, morbidity and mortality of Cushing\u2019s disease in Northern Ireland. Endocr Relat Cancer 31(9):e240028","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"1471_CR10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/ejendo\/lvae098","volume":"191","author":"Y Rudman","year":"2024","unstructured":"Rudman Y, Fleseriu M, Dery L, Masri-Iraqi H, Sasson L, Shochat T et al (2024) Endogenous Cushing\u2019s syndrome and cancer risk. Eur J Endocrinol 191(2):223\u2013231","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1471_CR11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cen.13600","volume":"88","author":"E Valassi","year":"2018","unstructured":"Valassi E, Feelders R, Maiter D, Chanson P, Yaneva M, Reincke M et al (2018) Worse health-related quality of life at long-term follow-up in patients with Cushing\u2019s disease than patients with cortisol producing adenoma. Data from the ERCUSYN. Clin Endocrinol (Oxf) 88(6):787\u2013798","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"1471_CR12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"1471_CR13","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO et al (2015) Treatment of Cushing\u2019s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807\u20132831","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1471_CR14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-13-0754","volume":"170","author":"C Giordano","year":"2014","unstructured":"Giordano C, Guarnotta V, Pivonello R, Amato MC, Simeoli C, Ciresi A et al (2014) Is diabetes in Cushing\u2019s syndrome only a consequence of hypercortisolism? Eur J Endocrinol 170(2):311\u2013319","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1471_CR15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ejendo\/lvad008","volume":"188","author":"V Amodru","year":"2023","unstructured":"Amodru V, Ferriere A, Tabarin A, Castinetti F, Tsagarakis S, Toth M et al (2023) Cushing\u2019s syndrome in the elderly: data from the European Registry on Cushing\u2019s Syndrome. Eur J Endocrinol 188(4):395\u2013406","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1471_CR16","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/HJH.0000000000003252","volume":"40","author":"F Fallo","year":"2022","unstructured":"Fallo F, Di Dalmazi G, Beuschlein F, Biermasz NR, Castinetti F, Elenkova A et al (2022) Diagnosis and management of hypertension in patients with Cushing\u2019s syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 40(11):2085\u20132101","journal-title":"J Hypertens"},{"issue":"1","key":"1471_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12020-018-1819-6","volume":"64","author":"MH Schernthaner-Reiter","year":"2019","unstructured":"Schernthaner-Reiter MH, Siess C, Gessl A, Scheuba C, Wolfsberger S, Riss P et al (2019) Factors predicting long-term comorbidities in patients with Cushing\u2019s syndrome in remission. Endocrine 64(1):157\u2013168","journal-title":"Endocrine"},{"issue":"4","key":"1471_CR18","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","volume":"99","author":"X Bertagna","year":"2014","unstructured":"Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A et al (2014) LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 99(4):1375\u20131383","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1471_CR19","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A et al (2020) Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre Phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8(9):748\u2013761","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"1471_CR20","doi-asserted-by":"crossref","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","volume":"107","author":"M Gadelha","year":"2022","unstructured":"Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A et al (2022) Randomized trial of osilodrostat for the treatment of Cushing disease. J Clin Endocrinol Metab 107(7):e2882\u2013e2895","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1471_CR21","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s40618-024-02359-6","volume":"47","author":"R Pivonello","year":"2024","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Shimatsu A, Feelders RA, Kadioglu P et al (2024) Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing\u2019s disease. J Endocrinol Invest 47(10):2437\u20132448","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"1471_CR22","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M et al (2014) Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a Phase III study. Clin Endocrinol (Oxf) 81(3):408\u2013417","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Suppl 1","key":"1471_CR23","first-page":"S20","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2023","unstructured":"American Diabetes Association Professional Practice Committee (2023) 2. Diagnosis and classification of diabetes: standards of care in diabetes \u2013 2024. Diabetes Care 47(Suppl 1):S20\u2013S42","journal-title":"Diabetes Care"},{"issue":"4","key":"1471_CR24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-22-0317","volume":"187","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Newell -Price J, Pivonello R, Shimatsu A, Auchus RJ, Scaroni C et al (2022) Long-term outcomes of osilodrostat in Cushing\u2019s disease: LINC 3 study extension. Eur J Endocrinol 187(4):531\u2013541","journal-title":"Eur J Endocrinol"},{"key":"1471_CR25","doi-asserted-by":"crossref","first-page":"1236465","DOI":"10.3389\/fendo.2023.1236465","volume":"14","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Snyder PJ, Witek P, Bex M, Belaya Z, Turcu AF et al (2023) Long-term efficacy and safety of osilodrostat in patients with Cushing\u2019s disease: results from the LINC 4 study extension. Front Endocrinol (Lausanne) 14:1236465","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1471_CR26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/cen.12259","volume":"80","author":"S Petersenn","year":"2014","unstructured":"Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K et al (2014) High variability in baseline urinary free cortisol values in patients with Cushing\u2019s disease. Clin Endocrinol (Oxf) 80(2):261\u2013269","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1471_CR27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fendo.2019.00321","volume":"10","author":"M Barbot","year":"2019","unstructured":"Barbot M, Ceccato F, Scaroni C (2019) The pathophysiology and treatment of hypertension in patients with Cushing\u2019s syndrome. Front Endocrinol (Lausanne) 10:321","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1471_CR28","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2265.2004.02168.x","volume":"61","author":"T Mancini","year":"2004","unstructured":"Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G (2004) High cardiovascular risk in patients with Cushing\u2019s syndrome according to 1999 WHO\/ISH guidelines. Clin Endocrinol (Oxf) 61(6):768\u2013777","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Suppl 1","key":"1471_CR29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000314315","volume":"92","author":"MV Cicala","year":"2010","unstructured":"Cicala MV, Mantero F (2010) Hypertension in Cushing\u2019s syndrome: from pathogenesis to treatment. Neuroendocrinology 92(Suppl 1):44\u201349","journal-title":"Neuroendocrinology"},{"issue":"8","key":"1471_CR30","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/1060028020968808","volume":"55","author":"JA Dougherty","year":"2021","unstructured":"Dougherty JA, Desai DS, Herrera JB (2021) Osilodrostat: a novel steroidogenesis inhibitor to treat Cushing\u2019s disease. Ann Pharmacother 55(8):1050\u20131060","journal-title":"Ann Pharmacother"},{"issue":"6","key":"1471_CR31","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11102-022-01268-2","volume":"25","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Biller BMK (2022) Treatment of Cushing\u2019s syndrome with osilodrostat: practical applications of recent studies with case examples. Pituitary 25(6):795\u2013809","journal-title":"Pituitary"},{"issue":"11","key":"1471_CR32","doi-asserted-by":"crossref","first-page":"e0166077","DOI":"10.1371\/journal.pone.0166077","volume":"11","author":"A Kamba","year":"2016","unstructured":"Kamba A, Daimon M, Murakami H, Otaka H, Matsuki K, Sato E et al (2016) Association between higher serum cortisol levels and decreased insulin secretion in a general population. PLoS One 11(11):e0166077","journal-title":"PLoS ONE"},{"key":"1471_CR33","doi-asserted-by":"crossref","first-page":"1174119","DOI":"10.3389\/fendo.2023.1174119","volume":"14","author":"A Mehlich","year":"2023","unstructured":"Mehlich A, Bolanowski M, Mehlich D, Witek P (2023) Medical treatment of Cushing\u2019s disease with concurrent diabetes mellitus. Front Endocrinol (Lausanne) 14:1174119","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"1471_CR34","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1210\/clinem\/dgac265","volume":"107","author":"P Limumpornpetch","year":"2022","unstructured":"Limumpornpetch P, Morgan AW, Tiganescu A, Baxter PD, Nyawira Nyaga V, Pujades-Rodriguez M et al (2022) The effect of endogenous Cushing syndrome on all-cause and cause-specific mortality. J Clin Endocrinol Metab 107(8):2377\u20132388","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1471_CR35","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1210\/jc.2018-02524","volume":"104","author":"O Ragnarsson","year":"2019","unstructured":"Ragnarsson O, Olsson DS, Papakokkinou E, Chantzichristos D, Dahlqvist P, Segerstedt E et al (2019) Overall and disease-specific mortality in patients with Cushing disease: a Swedish nationwide study. J Clin Endocrinol Metab 104(6):2375\u20132384","journal-title":"J Clin Endocrinol Metab"},{"issue":"20","key":"1471_CR36","doi-asserted-by":"crossref","first-page":"12305","DOI":"10.3390\/ijms232012305","volume":"23","author":"P El Meouchy","year":"2022","unstructured":"El Meouchy P, Wahoud M, Allam S, Chedid R, Karam W, Karam S (2022) Hypertension related to obesity: pathogenesis, characteristics and factors for control. Int J Mol Sci 23(20):12305","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1471_CR37","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/01.CIR.67.5.968","volume":"67","author":"HB Hubert","year":"1983","unstructured":"Hubert HB, Feinleib M, McNamara PM, Castelli WP (1983) Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67(5):968\u2013977","journal-title":"Circulation"},{"issue":"11","key":"1471_CR38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","volume":"7","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu M, Pivonello R, Elenkova A, Salvatori R, Auchus RJ, Feelders RA et al (2019) Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing\u2019s syndrome (SONICS): a Phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol 7(11):855\u2013865","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1471_CR39","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1530\/EJE-22-0506","volume":"187","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Auchus RJ, Greenman Y, Zacharieva S, Geer EB, Salvatori R et al (2022) Levoketoconazole treatment in endogenous Cushing\u2019s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes. Eur J Endocrinol 187(6):859\u2013871","journal-title":"Eur J Endocrinol"},{"key":"1471_CR40","doi-asserted-by":"crossref","first-page":"1017331","DOI":"10.3389\/fendo.2022.1017331","volume":"13","author":"C Viecceli","year":"2022","unstructured":"Viecceli C, Mattos ACV, Costa MCB, de Melo RB, Rodrigues TDC, Czepielewski MA (2022) Evaluation of ketoconazole as a treatment for Cushing\u2019s disease in a retrospective cohort. Front Endocrinol (Lausanne) 13:1017331","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Suppl 1","key":"1471_CR41","doi-asserted-by":"crossref","first-page":"A515","DOI":"10.1210\/jendso\/bvab048.1053","volume":"5","author":"LK Nieman","year":"2021","unstructured":"Nieman LK, Boscaro M, Scaroni CM, Deutschbein T, Mezosi E, Driessens N et al (2021) Metyrapone treatment in endogenous cushing\u2019s syndrome: results at week 12 from PROMPT, a prospective international multicenter, open-label, Phase III\/IV study. J Endocr Soc 5(Suppl 1):A515","journal-title":"J Endocr Soc"},{"key":"1471_CR42","doi-asserted-by":"crossref","unstructured":"Nieman L, Boscaro M, Carla S, Deutschbein T, Mezosi E, Driessens N et al (2021) Metyrapone treatment in endogenous Cushing\u2019s syndrome. Long term efficacy and safety results of the extension of the Phase III\/IV study PROMPT. Endocr Abstracts 73:abst OC3.3","DOI":"10.1530\/endoabs.73.OC3.3"},{"issue":"10","key":"1471_CR43","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M et al (2012) A 12-month Phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366(10):914\u2013924","journal-title":"N Engl J Med"},{"issue":"1","key":"1471_CR44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","volume":"6","author":"A Lacroix","year":"2018","unstructured":"Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P et al (2018) Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 6(1):17\u201326","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1471_CR45","doi-asserted-by":"crossref","first-page":"1165681","DOI":"10.3389\/fendo.2023.1165681","volume":"14","author":"RA Feelders","year":"2023","unstructured":"Feelders RA, Fleseriu M, Kadioglu P, Bex M, Gonz\u00e1lez-Devia D, Boguszewski CL et al (2023) Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing\u2019s disease. Front Endocrinol (Lausanne) 14:1165681","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1471_CR46","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/cen.14081","volume":"91","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu M, Petersenn S, Biller BMK, Kadioglu P, De Block C, T\u2019Sjoen G et al (2019) Long-term efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a Phase III extension study. Clin Endocrinol (Oxf) 91(6):776\u2013785","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"1471_CR47","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1530\/EC-20-0361","volume":"9","author":"MR Gadelha","year":"2020","unstructured":"Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I et al (2020) Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect 9(12):1178\u20131190","journal-title":"Endocr Connect"},{"issue":"6","key":"1471_CR48","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","volume":"24","author":"SL Samson","year":"2021","unstructured":"Samson SL, Gu F, Feldt-Rasmussen U, Zhang S, Yu Y, Witek P et al (2021) Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. Pituitary 24(6):887\u2013903","journal-title":"Pituitary"},{"issue":"6","key":"1471_CR49","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BMK, Findling JW, Molitch ME, Schteingart DE, Gross C et al (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 97(6):2039\u20132049","journal-title":"J Clin Endocrinol Metab"},{"key":"1471_CR50","doi-asserted-by":"crossref","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison C Himmelfarb et al (2018) 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71(6):e13\u2013e115","DOI":"10.1161\/HYP.0000000000000065"},{"issue":"38","key":"1471_CR51","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C et al (2024) 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 45(38):3912\u20134018","journal-title":"Eur Heart J"},{"issue":"6","key":"1471_CR52","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s11102-022-01263-7","volume":"25","author":"R Pivonello","year":"2022","unstructured":"Pivonello R, Zacharieva S, Elenkova A, T\u00f3th M, Shimon I, Stigliano A et al (2022) Levoketoconazole in the treatment of patients with endogenous Cushing\u2019s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pituitary 25(6):911\u2013926","journal-title":"Pituitary"},{"issue":"6","key":"1471_CR53","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C et al (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 97(6):2039\u20132049","journal-title":"J Clin Endocrinol Metab"}],"updated-by":[{"DOI":"10.1007\/s11102-025-01525-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000}}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01471-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01471-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01471-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:25:53Z","timestamp":1792200353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01471-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1471"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01471-3","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"12 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised and Figure 2 has been replaced with correct figure.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11102-025-01525-0","URL":"https:\/\/doi.org\/10.1007\/s11102-025-01525-0","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The LINC 3 and LINC 4 studies were conducted in accordance with the Declaration of Helsinki, and study protocols were approved by independent ethics committees\/institutional review boards.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients provided written informed consent to participate at the start of the core and extension phases of the studies.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients provided written informed consent for their data to be published anonymously.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MF reports grants to her university from Crinetics and Sparrow and occasional scientific consulting fees from Crinetics, Recordati Rare Diseases, Sparrow, and Xeris Pharmaceuticals; she served as a member of the LINC 3 steering committee and is a member of the editorial board of Pituitary. RP has received research funding from Recordati AG, Corcept Therapeutics, Xeris Pharmaceuticals (Strongbridge), Neurocrine Biosciences, and Spruce Biosciences and has served as a consultant for Corcept Therapeutics, Recordati AG, Crinetics Pharmaceuticals, and H Lundbeck A\/S. JN-P reports research grants and consultancy payments to his university from Crinetics, Diurnal, HRA Pharma, and Recordati Rare Diseases. MRG has received speaker fees from Recordati, Ipsen, Novo Nordisk, and Camurus and attended advisory boards for Novo Nordisk, Recordati, and Crinetics Pharmaceuticals. BMKB reports occasional consulting honoraria from H Lundbeck A\/S, Recordati Rare Diseases, Sparrow, and Xeris Pharmaceuticals; she served on the LINC 3 steering committee. RJA reports grants and personal fees from Xeris Pharmaceuticals, Spruce Biosciences, Neurocrine Biosciences, Corcept Therapeutics, Diurnal Ltd, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, and Recordati Rare Diseases and personal fees from Adrenas Therapeutics, Quest Diagnostics, H Lundbeck A\/S, Novo Nordisk, and Besins Pharmaceuticals. RF reports consultancy for Corcept Therapeutics and Recordati and research grants from Strongbridge and Corcept Therapeutics. AS reports serving as a speaker and consultant for Recordati; he was also a member of the LINC 3 steering committee. PW reports receiving travel grants and speaker fees from Novartis, Ipsen, Recordati, Novo Nordisk, Strongbridge Biopharma, Merck-Serono, Lilly, and Berlin Chemie. MB reports consultancy for and travel grants from Recordati. AP is an employee of Recordati. AMP was an employee of Recordati at the time the analyses were conducted. AL reports grants and personal consulting fees from Novartis, Recordati, Pfizer, and Corcept Therapeutics.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22"}}